Missing Information
  • A System Error Has Occured:0177 - Failed to Load All Sections.
Company:  AVEO PHARMACEUTICALS INC (AVEO)
Form Type:  10-K
Filing Date:  3/11/2013 
CIK:  0001325879 
Address:  ONE BROADWAY
14TH FLOOR
 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617- 531-2130 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.09  
Change: 
0.14 (7.18%)  
Trade Time: 
Jun 27  
Market Cap: 
$230.66M
Trade AVEO now with 

© 2017  
Description of Business
We are a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. Our proprietary platform has delivered unique insights into cancer and related diseases. Our strategy is to leverage these biomarker insights and partner resources to advance the development of our clinical pipeline. We are focused on developing our lead candidate tivozanib in North America as a treatment for renal cell carcinoma, or RCC. In addition, we have entered into partnerships to fund the further development and commercialization of our clinical stage assets, including AV-380, ficlatuzumab, AV-203, and tivozanib for oncology indications outside of North America and for non-oncologic indications worldwide. We are currently seeking a partner to develop the AV-353 platform, a preclinical asset, worldwide for the potential treatment of pulmonary arterial hypertension, or PAH.